BMS’ Opdivo Fails as PD-L1 Monotherapy in Untreated NSCLC, Giving Edge to Merck

Drug Industry Daily
A A
Bristol-Myers Squibb presented results from several clinical trials of its PD-L1 immunotherapy, Opdivo, including more detailed data from a Phase III trial that failed to show benefits as a first-line monotherapy in advanced non-small cell lung cancer.

To View This Article:

Login

Subscribe To Drug Industry Daily